JLH (Hans) Evers, the Editor-in-Chief of the publication Human Reproduction shared this summary of a recent study called “Intent to treat analysis of in vitro fertilization and preimplantation genetic screening versus expectant management in patients with recurrent pregnancy loss.”
In this month’s issue of Human Reproduction, Gayathree Murugappan and colleagues from Stanford and Seattle show that among all attempts at preimplantation genetic screening (PGS) or expectant management in patients with recurrent pregnancy loss (RPL), clinical outcomes including pregnancy rate, live birth rate and clinical miscarriage rate were similar. They conclude that success rates with PGS are limited by the high incidence of cycles that intend to apply PGS but subsequently cancel it, and by cycles that do not reach transfer.
Counseling RPL patients on their treatment options should include not only success rates with PGS per euploid embryo transferred, but also live birth rate per initiated PGS-intending cycle. Patients who express urgency to conceive should be counseled that PGS might not accelerate their time to conception.
For the full article and summary of the data, please click here.